Venture capital investment in biopharmaceutical companies during 2019 fell from the records set in 2018, but still came in second place by a wide margin, according to recent year-end wrap-ups – Silicon Valley Bank (SVB)’s annual Healthcare Investments & Exits report and the Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA).
SVB said drug developers in the US and Europe raised $15.64bn in 2019 versus $17.1bn in 2018, while Pitchbook and the NVCA said 866 biopharma firms brought in $16.6bn globally last year versus 831 that garnered $18.6bn in the prior year